MEDICINOVA REPORTS MN-305 RESULTS

A A

MediciNova has announced the results of its Phase II/III randomized, double-blind, placebo-controlled clinical trial of MN-305 in 416 patients with generalized anxiety disorder (GAD).

Trends for improvement in all efficacy outcome measures were observed in patients treated with MN-305. Statistically significant improvements in item 1 of the HAM-A (anxious mood) were observed through eight weeks of treatment with MN-305, however, statistical significance on the primary outcome measure of the trial (change from baseline in the Hamilton Anxiety Rating Scale total score) was not achieved. MN-305 was well-tolerated at all doses in the trial.